Otitis Media - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Pipeline Review, H1 2017, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Otitis Media - Overview
Otitis Media - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Otitis Media - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Otitis Media - Companies Involved in Therapeutics Development
Cellceutix Corp
ContraFect Corp
GlaxoSmithKline Plc
Lee's Pharmaceutical Holdings Ltd
Madam Therapeutics BV
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Otonomy Inc
Yuhan Corp
Otitis Media - Drug Profiles
(cholesteryl palmitate + colfosceril palmitate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
betahistine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2189242A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazufloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCL-1440 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal (23-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Otitis Media - Dormant Projects
Otitis Media - Product Development Milestones
Featured News & Press Releases
Nov 02, 2016: Otonomy Announces Assignment of J Code for OTIPRIO
Oct 07, 2016: Otonomy Holds Investor and Analyst Day and Provides Corporate Update
Oct 04, 2016: Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes
Sep 15, 2016: Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO in Patients with History of Otitis Media Requiring Tympanostomy Tubes
May 20, 2016: Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO
May 16, 2016: Otonomy Announces OTIPRIO Data Presentation and Symposium at Combined Otolaryngology Spring Meetings
Mar 18, 2016: Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology
Mar 03, 2016: Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
Mar 02, 2016: Otonomy Announces Commercial Availability of OTIPRIO
Dec 11, 2015: Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
Nov 03, 2015: Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes
Sep 24, 2015: Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting
May 07, 2015: Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
Apr 28, 2015: Otonomy Announces FDA Acceptance of AuriPro New Drug Application
Apr 27, 2015: Otonomy Presents AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Otitis Media, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Otitis Media - Pipeline by Cellceutix Corp, H1 2017
Otitis Media - Pipeline by ContraFect Corp, H1 2017
Otitis Media - Pipeline by GlaxoSmithKline Plc, H1 2017
Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
Otitis Media - Pipeline by Madam Therapeutics BV, H1 2017
Otitis Media - Pipeline by Merck & Co Inc, H1 2017
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2017
Otitis Media - Pipeline by Otonomy Inc, H1 2017
Otitis Media - Pipeline by Yuhan Corp, H1 2017
Otitis Media - Dormant Projects, H1 2017